Please use this identifier to cite or link to this item:
10.1056/NEJMoa1203859
Title: | N-3 fatty acids and cardiovascular outcomes in patients with dysglycemia |
Authors: | ORIGIN Trial Bosch, Jackie Gerstein, Hertzel C. Dagenais, Gilles R. Lejnieks, A. Markova, I. |
Keywords: | 3.2 Clinical medicine;1.1. Scientific article indexed in Web of Science and/or Scopus database;General Medicine;SDG 3 - Good Health and Well-being |
Issue Date: | 26-Jul-2012 |
Citation: | ORIGIN Trial , Bosch , J , Gerstein , H C , Dagenais , G R , Lejnieks , A & Markova , I 2012 , ' N-3 fatty acids and cardiovascular outcomes in patients with dysglycemia ' , New England Journal of Medicine , vol. 367 , no. 4 , pp. 309-318 . https://doi.org/10.1056/NEJMoa1203859 |
Abstract: | Background: The use of n-3 fatty acids may prevent cardiovascular events in patients with recent myocardial infarction or heart failure. Their effects in patients with (or at risk for) type 2 diabetes mellitus are unknown. Methods: In this double-blind study with a 2-by-2 factorial design, we randomly assigned 12,536 patients who were at high risk for cardiovascular events and had impaired fasting glucose, impaired glucose tolerance, or diabetes to receive a 1-g capsule containing at least 900 mg (90% or more) of ethyl esters of n-3 fatty acids or placebo daily and to receive either insulin glargine or standard care. The primary outcome was death from cardiovascular causes. The results of the comparison between n-3 fatty acids and placebo are reported here. Results: During a median follow up of 6.2 years, the incidence of the primary outcome was not significantly decreased among patients receiving n-3 fatty acids, as compared with those receiving placebo (574 patients [9.1%] vs. 581 patients [9.3%]; hazard ratio, 0.98; 95% confidence interval [CI], 0.87 to 1.10; P = 0.72). The use of n-3 fatty acids also had no significant effect on the rates of major vascular events (1034 patients [16.5%] vs. 1017 patients [16.3%]; hazard ratio, 1.01; 95% CI, 0.93 to 1.10; P = 0.81), death from any cause (951 [15.1%] vs. 964 [15.4%]; hazard ratio, 0.98; 95% CI, 0.89 to 1.07; P = 0.63), or death from arrhythmia (288 [4.6%] vs. 259 [4.1%]; hazard ratio, 1.10; 95% CI, 0.93 to 1.30; P = 0.26). Triglyceride levels were reduced by 14.5 mg per deciliter (0.16 mmol per liter) more among patients receiving n-3 fatty acids than among those receiving placebo (P<0.001), without a significant effect on other lipids. Adverse effects were similar in the two groups. Conclusions: Daily supplementation with 1 g of n-3 fatty acids did not reduce the rate of cardiovascular events in patients at high risk for cardiovascular events. (Funded by Sanofi; ORIGIN ClinicalTrials.gov number, NCT00069784.). |
Description: | Publisher Copyright: Copyright © 2012 Massachusetts Medical Society. |
DOI: | 10.1056/NEJMoa1203859 |
ISSN: | 0028-4793 |
Appears in Collections: | Research outputs from Pure / Zinātniskās darbības rezultāti no ZDIS Pure |
Files in This Item:
File | Size | Format | |
---|---|---|---|
n_3_Fatty_Acids_and_Cardiovascular_Outcomes_in_Patients_with_Dysglycemia.pdf | 635.37 kB | Adobe PDF | View/Open |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.